Journal
CLINICAL NEPHROLOGY
Volume 75, Issue 2, Pages 165-170Publisher
DUSTRI-VERLAG DR KARL FEISTLE
DOI: 10.5414/CN106491
Keywords
Castleman's disease; thrombotic microangiopathy; rituximab; monoclonal anti-CD20 antibody
Categories
Ask authors/readers for more resources
Thrombotic microangiopathy (TMA) is a rare renal complication accompanied with Castleman's disease. We report the first case of TMA combined plasma cell type multicentric Castleman's disease (MCD) which was successfully treated with rituximab and corticosteroid. A previously healthy 60-year-old Korean man was admitted due to acute renal failure, thrombocytopenia, and multiple lymphadenopathies. The result of lymph node biopsy was plasma cell type Castleman's disease and TMA was revealed by kidney biopsy. After treatment with rituximab, prednisolone and temporary hemodialysis, complete remission was achieved. The combination of corticosteroid and rituximab was associated with improvement for this patient.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available